AbbVie
ABBV · Biotechnology
$285.64
0.2%Pfizer
PFE · Pharmaceuticals
$30.03
1.3%The short version
- Pfizer is the larger business, with $62.6B of revenue in fiscal 2025 against $61.2B for AbbVie.
- AbbVie grew revenue faster (8.6%, against −1.7%).
- AbbVie turned more of its sales into free cash flow (29.1% FCF margin, against 14.5% FCF margin).
- AbbVie earned a higher return on the capital invested in it (15.7%, against 7.3%).
- Investors pay more for each dollar of AbbVie’s earnings: a P/E of 80.7x against 39.5x for Pfizer.
| Latest fiscal year | ABBV · FY25 | PFE · FY25 |
|---|---|---|
| Size | ||
| Market cap | $505.9B | $171.1B |
| Revenue | $61.2B | $62.6B |
| Free cash flow | $17.8B | $9.1B |
| Net income | $4.2B | $7.8B |
| Growth | ||
| Revenue growth | 8.6% | −1.7% |
| 5-year growth | 6.0% | 8.5% |
| Share count change | 0.0% | 0.2% |
| Profitability | ||
| Gross margin | 70.2% | 74.3% |
| Operating margin | 24.7% | — |
| Net margin | 6.9% | 12.4% |
| FCF margin | 29.1% | 14.5% |
| Return on capital | 15.7% | 7.3% |
| Return on equity | — | 8.9% |
| Balance sheet | ||
| Net debt | $61.8B | $54.3B |
| Net debt / EBITDA | 2.7x | 3.2x |
| Dividends and buybacks | $12.6B | $9.8B |
| Valuation & quality | ||
| P/E | 80.7x | 39.5x |
| Piotroski F-score | 7 | 6 |
FY16
ABBV $25.6B
PFE $52.8B
FY17
ABBV $28.2B
PFE $52.5B
FY18
ABBV $32.8B
PFE $40.8B
FY19
ABBV $33.3B
PFE $40.9B
FY20
ABBV $45.8B
PFE $41.7B
FY21
ABBV $56.2B
PFE $81.3B
FY22
ABBV $58.1B
PFE $101.2B
FY23
ABBV $54.3B
PFE $59.6B
FY24
ABBV $56.3B
PFE $63.6B
FY25
ABBV $61.2B
PFE $62.6B
ABBV
PFE
FY16
ABBV 36.4%
PFE —
FY17
ABBV 33.8%
PFE —
FY18
ABBV 19.5%
PFE —
FY19
ABBV 39.0%
PFE —
FY20
ABBV 24.8%
PFE —
FY21
ABBV 31.9%
PFE —
FY22
ABBV 31.2%
PFE —
FY23
ABBV 23.5%
PFE —
FY24
ABBV 16.2%
PFE —
FY25
ABBV 24.7%
PFE —
ABBV
PFE
FY16
ABBV $6.6B
PFE $14.4B
FY17
ABBV $9.4B
PFE $14.8B
FY18
ABBV $12.8B
PFE $13.8B
FY19
ABBV $12.8B
PFE $10.5B
FY20
ABBV $16.8B
PFE $12.2B
FY21
ABBV $22.0B
PFE $29.9B
FY22
ABBV $24.2B
PFE $26.0B
FY23
ABBV $22.1B
PFE $4.8B
FY24
ABBV $17.8B
PFE $9.8B
FY25
ABBV $17.8B
PFE $9.1B
ABBV
PFE
FY16
ABBV 22.7%
PFE 11.0%
FY17
ABBV 19.4%
PFE 15.6%
FY18
ABBV 22.6%
PFE 5.4%
FY19
ABBV 56.5%
PFE 12.8%
FY20
ABBV 20.9%
PFE 9.9%
FY21
ABBV 18.6%
PFE 32.0%
FY22
ABBV 20.8%
PFE 32.0%
FY23
ABBV 15.5%
PFE 2.5%
FY24
ABBV 15.0%
PFE 7.6%
FY25
ABBV 15.7%
PFE 7.3%
ABBV
PFE
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.